[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Apogee Therapeutics, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":44},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100593206","phase-2-a-long-term-safety-and-efficacy-study-evaluating-apg777-in-atopic-dermatitis-100593206",false,"NCT07003425","A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis","A Long-term Extension Study to Evaluate the Safety and Efficacy of APG777 in Patients With Atopic Dermatitis Previously Treated With APG777","Inclusion Criteria:\n\n* Participants who have completed the Treatment Period in a prior APG777 study and were, in the Investigator's opinion, compliant with the study protocol\n* Participants who, in the Investigator's opinion, would benefit from long-term treatment with APG777\n* Use the same non-prescription non-medicated emollient\u002Fmoisturizer of their choice from the last day of the Parent Study and throughout the LTE study\n\nExclusion Criteria:\n\n* Participants who have developed an AE while participating in the Parent Study, which, in the opinion of the Investigator or of the Medical Monitor, could indicate that continued treatment with APG777 may present an unreasonable risk for the patient\n* Participants who terminated early from the Parent Study or permanently discontinued the study drug during the Parent Study\n* Use of any of the prohibited medications from Screening Visit (Visit 1) of the LTE study\n* Presence of dermatologic conditions and\u002For comorbidities that might confound the diagnosis of AD and\u002For interfere with study assessments\n\nNote: Additional protocol defined Inclusion\u002FExclusion criteria may apply","ALL","18 Years",{"count":19,"type":20},350,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This is a multicenter, double-blind, Long-Term Extension (LTE) study to evaluate the long-term safety and efficacy of APG777 in patients with moderate-to-severe AD who have completed treatment in an APG777 Parent Study (NCT06395948).\n\nThe LTE study will consist of 3 periods: 1) Screening Visit will coincide with the last visit of the Maintenance Period in the Parent Study 2) Extended Treatment Period 3) Post-treatment Follow-up Period.\n\nThis study will be conducted in participants with atopic dermatitis (AD) who completed the Treatment Period in a prior APG777 study and who, in the opinion of the Investigator, would benefit from long-term treatment with APG777.",[26],"Atopic Dermatitis",[26,28,29,30],"APG777","Safety","Efficacy","RECRUITING","2026-06-30",{"date":34,"type":35},"2026-07-01","ACTUAL",{"date":37,"type":35},"2025-05-14",{"date":39,"type":20},"2029-12",{"name":41,"class":42},"Apogee Therapeutics, Inc.","INDUSTRY",61,""]